Novavax's banner
Novavax's profile picture

Novavax

@Novavax60,240 subscribers

Producing next-generation vaccines to help protect health through partnerships and R&D. See what’s developing at https://t.co/KU31yMhv7w & https://t.co/vOlgl99GU0

Shorts

We are proud to share that our COVID-19 vaccine is expected to be available at thousands of locations across major retail pharmacies in the U.S., including CVS Pharmacy, Rite Aid, Walgreens, Costco, Sam’s Club, Walmart, Kroger, Meijer, and Publix. Find a Novavax vaccine near you: Link to press release:

We are proud to share that our COVID-19 vaccine is expected to be available at thousands of locations across major retail pharmacies in the U.S., including CVS Pharmacy, Rite Aid, Walgreens, Costco, Sam’s Club, Walmart, Kroger, Meijer, and Publix. Find a Novavax vaccine near you: Link to press release:

163,851 просмотров

#NEWS: Novavax has entered into a non-exclusive license agreement with Pfizer Inc. for use of Novavax’s Matrix-M® adjuvant for up to two disease areas. This new partnership shows our corporate strategy in action, and adds to the successful collaboration we have with Sanofi, among other major companies. We’re excited to be executing on our strategy to drive incremental value from partnerships and R&D innovation, with the potential to create new or improve existing products using Novavax’s differentiated technology platform. Ultimately, these partnerships increase access for the people who could benefit from products built with our technology and importantly drive incremental value for investors and for global public health. Visit to get details on the potential value we are building with this partnership, including $30 million upfront, up to $500 million in milestone payments and more. We’re excited to work with you, Pfizer. Read more:

#NEWS: Novavax has entered into a non-exclusive license agreement with Pfizer Inc. for use of Novavax’s Matrix-M® adjuvant for up to two disease areas. This new partnership shows our corporate strategy in action, and adds to the successful collaboration we have with Sanofi, among other major companies. We’re excited to be executing on our strategy to drive incremental value from partnerships and R&D innovation, with the potential to create new or improve existing products using Novavax’s differentiated technology platform. Ultimately, these partnerships increase access for the people who could benefit from products built with our technology and importantly drive incremental value for investors and for global public health. Visit to get details on the potential value we are building with this partnership, including $30 million upfront, up to $500 million in milestone payments and more. We’re excited to work with you, Pfizer. Read more:

42,824 просмотров

#NEWS: Novavax completes U.S. marketing authorization transfer to @Sanofi for Nuvaxovid™, following the EU transfer in October in line with its collaboration and license agreement as well as its corporate strategy.

#NEWS: Novavax completes U.S. marketing authorization transfer to @Sanofi for Nuvaxovid™, following the EU transfer in October in line with its collaboration and license agreement as well as its corporate strategy.

13,359 просмотров

We have a clear corporate growth strategy and many near-term milestones to look forward to in 2025. Read more:

We have a clear corporate growth strategy and many near-term milestones to look forward to in 2025. Read more:

13,153 просмотров

Videos

Больше нет контента для загрузки